Cite

    M. Genovese et al.. “OP0021 A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: Naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors.” Annals of the rheumatic diseases, vol. 71, n.d., p. 59. http://access.bl.uk/ark:/81055/vdc_100137791675.0x00005d